Jinyu Bio gets approval for new brucellosis vaccine

Jinyu Bio-Technology Co., Ltd. (600201.SS) announced that its wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceuticals Co., Ltd., has received a new veterinary drug registration certificate for its jointly developed Brucellosis gene-deleted live vaccine (RM6 strain, rough type). The vaccine, designed to prevent ovine Brucellosis, boasts an immunity period of 12 months post-vaccination and requires a subcutaneous injection. The new vaccine complements Jinyu Bio's existing Brucellosis vaccine offerings, forming a comprehensive product portfolio. With cumulative R&D investment of approximately ¥10.6 million, Jinyu Bio anticipates that the new registration will enhance its research capabilities, market competitiveness, and sustainable development. The company's Brucellosis vaccine batch release volume ranks among the highest in the industry in 2024.